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ABSTRACT
Background and Aims A combination of behavioural and pharmacological support is judged to be the optimal ap-
proach for assisting smoking cessation. Allen Carr’s Easyway (ACE) is a single-session pharmacotherapy-free programme
that has been in operation internationally for 38 years. We compared the effectiveness of ACE with specialist behavioural
and pharmacological support delivered to the national standard in England. Design A two-arm, parallel-group, single-
blind, randomized controlled trial. Setting London, UK, between February 2017 and May 2018. Participants A total
of 620 participants (310 in ACE and 310 in the combined behavioural and pharmacological support condition) were in-
cluded in the analysis. Adult (≥ 18 years) smokers wanting to quit were randomized in a 1 : 1 ratio. Mean age for the total
sample was 40.8 years, with 53.4% being male. Participant baseline characteristics (ethnicity, educational level, number
of previous quit attempts, nicotine dependence) were evenly balanced between treatment groups. Intervention and
comparator The intervention was the ACE method of stopping smoking. This centres on a 4.5–6-hour session of
group-based support, alongside subsequent text messages and top-up sessions if needed. It aims to make it easy to stop
smoking by convincing smokers that smoking provides no beneﬁts for them. The comparator was a specialist stop
smoking service (SSS) providing behavioural and pharmacological support in accordance with national standards.
Measurements The primary outcome was self-reported continuous abstinence for 26 weeks from the quit/quit re-set
date veriﬁed by exhaled breath carbon monoxide measurement < 10 parts per million (p.p.m.). Primary analysis was by
intention to treat. Secondary outcomes were: use of pharmacotherapy, adverse events and continuous abstinence up to
4 and 12weeks. Findings A total of 468 participants attended treatment (255 ACE versus 213 SSS, P< 0.05). Of those
who did attend treatment, 100 completed 6-month measures (23.7% ACE versus 20.7% SSS). Continuous abstinence to
26weekswas 19.4% (60 of 310) in theACE intervention and 14.8% (46 of 310) in the SSS intervention [risk difference for
ACE versus SSS 4.5% (95% conﬁdence interval (CI) = –1.4 to 10.4%, odds ratio (OR) = 1.38)]. The Bayes factor for supe-
riority of the ACE condition was 1.24. Conclusion There was no clear evidence of a difference in the efﬁcacies of the Al-
len Carr’s Easyway (ACE) and specialist smoking cessation support involving behavioural support and pharmacotherapy.
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INTRODUCTION
Although theWorld Health Organization (WHO) [1] report
that the prevalence of tobacco smoking is declining
world-wide, in 2017 in England alone 14.9% of adults
were classiﬁed as smokers, with 77,900 deaths attributed
to smoking [2]. Many smokers want to quit and oftenmake
several attempts to do so, but the majority fail due to both
physiological and psychological factors [3]. Over the years,
researchers have sought to develop effective cessation
treatments (psychological and pharmacological) in an
effort to provide education and support. Although evidence
suggests that these types of intervention are cost-effective
from a public health perspective, a recent report showed
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that 37% of smokersmade an attempt to quit but only 19%
were successful in the short term [4]. In addition, many
people fail to maintain smoking cessation in the longer
term [5,6].
It is important to understand and continually evaluate
the relative efﬁcacies of various interventions designed to
help people quit smoking, and to develop the evidence base
for methods which, while well-established, have not been
tested systematically. One such treatment offered in the
United Kingdom is the Allen Carr’s Easyway (ACE) method
of stopping smoking. While the ACE method is well
established and its efﬁcacy has received some empirical
support [7,8], there has not been a full trial to date testing
the efﬁcacy of this method using the Russell Standard as
the outcome measure (the benchmark cessation measure)
or a comparison against a specialist stop smoking service
(SSS) providing behavioural and pharmacological support
in accordance with national standards (a highly effective
stop smoking intervention offered in the United
Kingdom) [9,10]. Evaluating the efﬁcacy of the ACE
method is important, as it offers a pharmacotherapy-free
method of smoking cessation which can be delivered in
group therapy sessions. As such, it may offer a viable
cost-effective additional treatment option in
public/funded health-care settings. In the current study,
we conducted a parallel group, randomized controlled
trial to compare the efﬁcacy of the ACE method and a
specialist stop smoking service (SSS) providing behav-
ioural and pharmacological support.
METHODS
Study design
A two-arm, parallel group, single-blind, randomized con-
trolled trial, conducted in London, UK. First randomization
was on 3 February 2017, and the last follow up on 25May
2018. The published protocol describes procedures in de-
tail [11].
Participants
People were eligible if aged 18 years or older, were current
smokers wanting to quit, were open to being randomly
assigned to one of two treatment conditions andwho could
provide consent. We excluded pregnant women; those
reporting a mental health condition or respiratory disease
such as asthma or emphysema; people whowere currently
enrolled on a similar clinical trial; and people whowere not
willing to undertake a stop smoking service which is
neither endorsed by the National Health Service (NHS)
nor National Institute for Health and Care Excellence
(NICE)-approved.
Procedure
We recruited via social media channels, newspaper and ra-
dio advertisements, and targeted e-mails to local businesses
and organizations asking people to contact the study cen-
tre for more information and eligibility pre-screening. This
was undertaken by research assistants, who also per-
formed follow-up assessments. The research team made
an initial contact attempt within 2 days to arrange a suit-
able time for pre-screening (with subsequent attempts over
the next 3 weeks, unless the participant withdrew). Partic-
ipants were not told at the point of pre-screening which
two interventions were being compared, just that the study
aimed to compare the efﬁcacy of two stop smoking inter-
ventions. If eligible, participants were asked about demo-
graphics, nicotine dependence and prior quit attempts to
allow for stratiﬁed randomization into the trial. Eligible par-
ticipants were sent a consent form immediately after pre-
screening and asked to return it within a week. On gaining
written consent, participants’ details were immediately
sent to the independent randomizer for allocation. Once
randomized, participant details were e-mailed to the allo-
cated intervention arm for them to make contact with
schedule treatment, which was recorded on a blind shared
ﬁle. Treatment arms attempted to make contact with par-
ticipants within the ﬁrst week of receiving the allocation.
Research assistants checked this ﬁle daily, and contacted
participants to arrange a face-to-face appointment to col-
lect baseline data (no more than 1 week before the treat-
ment date). Tests were administered by research
assistants at LSBU and participants were paid £15 for at-
tending each appointment. In addition, all participants
who completed the ﬁnal wave were entered into a rafﬂe
for a holiday and other (low-value) prizes. Data collection
continued as scheduled if participants discontinued
treatments.
The Fulham Research Ethics Committee approved the
research protocol (ref: 16/LO/1657), as did the London
South Bank University (LSBU) ethics panel (UEP0516).
Randomization and masking
Participants whomet the inclusion criteria and gave details
about demographics and nicotine dependence [Fagerstrom
Test for Nicotine Dependence (FTND[12])] were random-
ized by the study statistician (S.W.) in a 1 : 1 ratio to either
the ACE or NHS treatments, with computerized block ran-
domization stratiﬁed by age (18–37 or > 38 years), sex
(male or female), number of previous quit attempts (none
made over the past year or attempts reported over the past
year) and level of nicotine dependence (> 5 or ≤ 5 FTND).
The stratiﬁcation variables were selected as they have been
shown to inﬂuence treatment success, and our aim was to
investigate the unique effects of treatment across a
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demographically heterogeneous sample. Participants were
blind to both treatments until randomized, and once allo-
cated were blind to the treatment not being received.
Treatment staff were not blind to participants taking part
in the trial. Members of the trial steering committee, man-
agement committee and other teammembers (with the ex-
ception of the statistician/randomizer) remained blind to
treatment allocation until the ﬁnal follow-up was com-
pleted and the analysis undertaken recorded. The analysis
protocol and syntax were prepared and lodged with the
Open Science Framework (OSF) before the statistician
was provided with the data set.
Interventions
Allen Carr’s Easyway programme
Participants randomized to the ACE treatment arm
attended a single group session at their choice of either
LSBU (2 days a week) or Allen Carr’s London treatment
centre (6 days a week, afternoon only). The session lasted
4.5–6 hours and comprised elements of cognitive–
behavioural therapy (CBT) with a brief relaxation exercise
at the end that serves to reinforce the main points covered.
Participants were encouraged to carry on smokingas usual
prior to attending the session and to take advantage of
scheduled smoking breaks (every 45–60 minutes) before
ﬁnishing with a ﬁnal ‘ritual’ cigarette. A trained facilitator
worked with participants to help them recognize the
positive expectancies they associate with smoking (e.g.
pleasure, support) as a crutch, before moving towards the
conclusion that any beliefs about smoking being of beneﬁt
to the individual are harmful. Participantswere also taught
how the psychological and pharmacological mechanisms
of nicotine addiction facilitate the maintenance of a prob-
lematic belief system. Following the session, participants
were sent regular SMS messages from the clinical team
(standard procedure for this intervention) reminding them
to touch base with any questions they might have (for a
fuller description see the published protocol [11] and
Supporting information Appendix). One therapist delivered
each group session (seven therapists in total delivered
group sessions). The mean number of participants per
group was 8.95 [standard deviation (SD) = 4.08,
range = 1–19]. Participants could select which site to at-
tend: 197 attended their initial treatment session at LSBU
and 58 at ACE’s London treatment centre. There was no
difference in the primary outcome measure between sites
(χ2 = 0.87, P = 0.351).
Specialist stop smoking service (SSS)
Participants who received the SSS treatment attended a
single 30-minute session, which combined motivational
interviewing and CBT approaches and up to four follow-
up sessions (their standard treatment protocol). Sessions
took place at LSBU and were delivered by four SSS thera-
pists. Sessions were available 5 days a week in the morning
or afternoon. This constitutes the local NHS stop smoking
service currently offered at Guy’s and St Thomas’ NHS
Foundation Trust and Lambeth Public Health. In the ﬁrst
session, a therapist assessed current smoking, readiness
to quit and past quit attempts. Participants were then ad-
vised about nicotine dependence and withdrawal and the
pros and cons of pharmacotherapy discussed. Participants
were asked to set a quit date (within 2 weeks of attending
the ﬁrst session) and assisted to recognize and plan for
any upcoming high-risk situations which may lead to re-
lapse. Nicotine replacement therapy (NRT) was provided
using a voucher redeemable at local pharmacies in Lam-
beth and Southwark, and for Champix they were provided
with a letter of recommendation to take to their general
practitioner (GP) in order to request the prescribed medica-
tion. The intervention allowed for medications for up to
12 weeks in total. After the 4-week follow-up, participants
were prescribed 4 weeks’ supply and asked to contact the
SSS team to arrange the ﬁnal prescription (should one be
required). One, 2 and 3 weeks post-quit date participants
could return for a brief 10-minute progress check, includ-
ing a review of cessation coping mechanisms and pharma-
cotherapy supplies, and an opportunity to reﬂect on and
plan for any challenging situations encountered. At
4 weeks post-quit date, participants could return for a ﬁnal
10-minute meeting where they were advised about the
continued use of pharmacotherapy and techniques for cop-
ing with urges and cravings. At each appointment, partic-
ipants had their carbon monoxide levels measured and
feedback was provided by the clinician. Participants were
also urged to remain completely abstinent from cigarettes
(for a fuller description see the published protocol [11]).
Top-ups and re-sets
Both treatments contained, as standard, options to re-set
quit dates. The ACE provision allowed participants to
‘top-up’ their treatment through one or two additional ses-
sions that broadly followed the same format as the main
seminar, but were shorter at approximately 3.5 hours
and could be attended either face-to-face or online. Partic-
ipants receiving the SSS treatment were able to re-set their
quit date at the suggestion of the clinician. Participants
across both treatment arms were permitted a total of two
top-up sessions or opportunities to re-set within 12 weeks
of their original quit date. Any top-ups or re-sets were re-
corded by clinicians on a central shared ﬁle (containing
no condition data) and all follow-up assessments were cal-
culated according to the re-set date rather than the origi-
nal quit date (i.e. if a participant re-set a month after
their original quit date, all follow-ups moved to a month
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later). This design decision is addressed in more detail in
our protocol [11]. In the ACE arm, 36 attended a ﬁrst
top-up session at LSBU, 32 at the treatment centre and
22 received the top-up online (via an online webinar
replicating the content of face-to-face sessions). Fifteen
attended a third session at LSBU, 6 at the treatment
centre, and 12 received the session online.
Measures
Baseline
Quit efﬁcacy wasmeasured using four items: ‘I can achieve
my aims to quit smoking’; ‘I can cope with the demands of
quitting smoking’; ‘It is unlikely that I will do well at quit-
ting smoking’; ‘I think I can perform well at quitting
smoking’. A scale of 1 (strongly disagree) to 7 (strongly
agree) was used.
For use of support mechanisms (NRT, e-cigarettes,
Champix), participants were asked: ‘Have you regularly
used any of the following in the past few months?’ and
‘Are you planning on using any of the following when
you quit smoking?’ (yes/no answers).
Continuous smoking abstinence was biochemically ver-
iﬁed by exhaled breath carbon monoxide measurement [<
10 parts per million (p.p.m.)], using Bedfont Micro
Smokerlyzers. This is in line with the standard assessment
of smoking cessation used in research and practice in the
United Kingdom [10].
Nicotine dependence was measured using the
Fagerstrom Test for Nicotine Dependence [12].
Follow-ups at 4, 12 and 26 weeks
Quit efﬁcacy and continuous smoking abstinence were
measured as above.
For use of support mechanisms (NRT, e-cigarettes,
Champix), participants were asked: ‘Since we last met,
have you regularly used any of the following?’ and ‘Are
you planning on using any of the following when you quit
smoking?’ (yes/no answers).
Self-reported continuous abstinence from the quit/quit
re-set date was measured using ﬁve items: ‘Are you still
an ex-smoker?’; ‘Since we last met, have you had any ciga-
rettes? If so, how many?’; ‘How many cigarettes have you
had in the last week?’; and ‘Howmany cigarettes in the last
month?’; ‘In total, howmany cigarettes have you had since
your quit date?’
Nicotine dependence was measured using the
Fagerstrom Test for Nicotine Dependence [12].
For adverse events, participants were asked: ‘Have
you had any new medical issues which may be due to
your quit?’.
Sample size
The trial was designed to test for superiority on an
intention-to-treat (ITT) basis. In the Cochrane Review of
combined pharmacotherapy and behavioural interven-
tions for smoking cessation [9] a pooled quit rate of 17%
was found for interventions provided by specialist services.
This study was powered to detect, with 85% power, a 10%
advantage for ACE over the SSS (assuming it would per-
form as the specialist service providers) at a 5% signiﬁcance
level. Therefore, an initial sample of 620 participants was
sought (310 per intervention group).
Statistical analysis
Statistical analyseswere carried out using SPSS version 25.
The primary analyses used the ITTapproach at the point of
randomization (participants with unknown smoking sta-
tus were assumed to be smoking).
Primary outcome analysis
The primary outcome was continuous smoking abstinence
(self-reported abstinence over the whole follow-up period,
allowing ≤ 5 cigarettes in total since quit date) for 26weeks
from the quit/quit re-set date. Participants for whom
smoking cessation could not be conﬁrmed (i.e. are lost to
follow-up) were included in the analysis as failed quits in
line with the Russell Standard [10]. Absolute risk differ-
ences are presented with 95% conﬁdence intervals (CI).
Pearson’s χ2 analysis was used to test whether the risk dif-
ference differed signiﬁcantly from zero or not; exact P-
values are reported. ORs with 95% CIs are also reported,
calculated using logistic regression.
A series of sensitivity analyses were conducted to assess
the robustness of primary results with regards to deﬁnition
of the primary outcome. To investigate if the differential ef-
fects of interventions are present at each time-point (4 and
12weeks), the primary analysiswas repeated twice, the de-
pendent variable being smoking cessation conﬁrmed at 4
and 12 weeks. The primary analysis was repeated on
smoking cessation outcomes at both 12 and 26 weeks
using only participants who did not ‘re-set’ their quit dates
(SSS arm) or did not attend a top-up session (ACE arm). For
this analysis, this approach is preferable to including top-
ups/re-sets as failed quits, as many may, in fact, be success-
ful cessations. Estimates of effectiveness at 4, 12 and
26 weeks are also reported for only participants who
attended treatment. Stratiﬁcation variables were included
as covariates in logistic regression models when the full
sample (n = 620) was not used.
Secondary outcomes
Use of any NRT/e-cigarettes/Champix was analysed in the
same manner as the primary outcome using risk
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differences and adjusted ORs. Treatment arm and treat-
ment success were included as independent variables to-
gether with stratiﬁcation variables in the logistic
regression. These analyses were completed for (a) those
participants for whom NRT usage was known at 26 weeks
and those who had reported NRT use at 4 or 12 weeks, (b)
as in (a), but restricted to those who had attended treat-
ment, and (c) those participants followed-up at 26 weeks
(ignoring previous NRT use). A further secondary outcome
was completion of treatment (operationalized as atten-
dance at the ACE session or attendance at a minimum of
one SSS session).
RESULTS
Of 2115 people who were assessed, 133 did not meet the
eligibility criteria, 1358 declined to participate and 620
(29%)were randomized for inclusion into the study (Fig. 1).
Figure 1 Participant ﬂow [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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A total of 310 people were assigned to each treatment arm.
At 4 weeks, 49% of ACE participants completed follow-ups
and 43% for SSS; at 12 weeks the respective values are 46
and 38%; and for 26 weeks 29 and 28%. Thus, assumed
smoking rates (due to loss to follow up) at 26 weeks were
148 versus 170: a difference of 7.1% (95% CI = –1.0,
14.8%; P = 0.077). Of those attended treatment, 100
completed 6-month follow-up measures (23.7% ACE
versus 20.7% SSS); participants who had previously
indicated they had returned to smoking were not eligible
to complete these measures as their outcome status
was already known, see Fig. 1 for full participant ﬂow
details. Participants’ baseline characteristics were evenly
balanced between treatment groups (Table 1). Eighty-two
participants re-set their quit date, 33 in the SSS group
(three re-set twice, see Table S1 in Supporting
information Appendix for number of sessions attended)
and 49 in the ACE group (17 of them twice); 468
(75.5%) participants attended treatment. Treatment
attendance was signiﬁcantly higher in the ACE group
compared to the SSS group, P < 0.001 (see Table 2 for
number of sessions attended by treatment arm).
There was no evidence of a difference in rates of veriﬁed
continuous abstinence at 26 weeks between the ACE and
SSS groups, 19.4 versus 14.8% (risk difference = 4·5%;
95% CI =1.4, 10.4%; Table 3). This difference is not sta-
tistically signiﬁcant (P = 0.165). Given the non-signiﬁcant
ﬁnding a Bayes factor (B) was calculated (B = 1.24), indi-
cating non-conclusive evidence for the null hypothesis of
no difference. Risk differences for the 4- and 12-week
abstinence rates are also non-statistically signiﬁcant
(risk difference; 95% CIs = 5.8; 13.0 and 1.5%;
and 0.3, 6.8 and 6.2%, respectively).
Among self-reported quitters, three who self-reported
at 4 weeks failed veriﬁcation, three at 12 weeks and none
at 26 weeks. Similar estimates of treatment beneﬁt were
found in the sensitivity analyses.
No signiﬁcant difference was found when those who
re-set were classed as non-abstainers at 12 and 26 weeks.
In the SSS arm, six people who re-set were successful
Table 1 Baseline characteristics of participants.
ACE n = 310 SSS n = 310 Total n = 620
Age in years, mean (SD) 41·3 (11·1) 40·3 (11·8) 40·8 (11·5)
Male 170 (54·8%) 161 (51·9%) 331 (53·4%)
Ethnicity, n = 617 Indian 14 (4·5%) 13 (4·2%) 27 (4·4%)
Pakistani 5 (1·6%) 4 (1·3%) 9 (1·5%)
Bangladeshi 2 (0·6%) 3 (1·0%) 5 (0·8%)
Asian (other) 10 (3·2%) 10 (3·2%) 20 (3·2%)
Black: African 3 (1·0%) 10 (3·2%) 13 (2·1%)
Black: Caribbean 11 (3·6%) 21 (6·8%) 32 (5·2%)
Black: Other 8 (2·6%) 6 (1·9%) 14 (2·3%)
Mixed race 14 (4·5%) 20 (6·5%) 34 (5·5%)
White: UK or Irish 178 (57·8%) 157 (50·8%) 335 (54·3%)
White: Other European 41 (13·3%) 43 (13·9%) 84 (13·8%)
White: other 13 (4·2%) 16 (5·2%) 29 (4·7%)
Other 9 (2·9%) 6 (1·9%) 15 (2·4%)
Education achieved, n = 616 GCSE, CSE or equivalent 30 (9·7%) 24 (7·8%) 54 (8·8%)
A-Level 45 (14·6%) 43 (14·0%) 88 (14·3%)
Vocational qualiﬁcation 23 (7·4%) 23 (7·5%) 46 (7·5%)
Degree BA, BSc 116 (37·5%) 127 (41·4%) 243 (39·4%)
Postgraduate degree 69 (22·3%) 59 (19·2%) 128 (20·8%)
Other 26 (8·4%) 31 (10·1%) 57 (9·3%)
Number of cigarettes smoked/day, n = 619 10 or less 102 (32·9%) 135 (43·7%) 237 (38·3%)
11–20 163 (52·6%) 142 (46·0%) 305 (49·3%)
21–30 37 (11·9%) 27 (8·7%) 64 (10·3%)
More than 30 8 (2·6%) 5 (1·6%) 13 (2·1%)
Age started smoking (years), n = 617 17·1 (4·3) 16·6 (3·7) 16·9 (4·0)
Lives with other smokers, n = 617 105 (34·0%) 104 (33·8%) 209 (33·9%)
At least 1 quit attempt in past 12 months 196 (63·2%) 196 (63·2%) 392 (63·2%)
FTND score 5–8 129 (41·6%) 112 (36·1%) 241 (38·9%)
Quit efﬁcacy, n = 473 20·7 (4·3) 20·8 (4·1) 20·8 (4·2)
Baseline CO reading, n = 473 17.5 (9.8) 15.1 (10.2) 16.4 (10.1)
ACE = Allen Carr’s Easyway method. SSS = specialist stop smoking service (SSS) providing behavioural and pharmacological support in accordance with
national standards; CO = carbon monoxide; FTND = Fagerstrom Test for Nicotine Dependence; SD = standard deviation. All measures were taken before
randomization, n = 620 unless otherwise stated.
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quits at 26 weeks. In the ACE arm, nine were successful
at 26 weeks. The SSS group had statistically signiﬁcant
higher rates of veriﬁed abstinence at 4 weeks when
only analysing those participants who had attended
treatment.
Use of pharmacotherapy was signiﬁcantly higher in the
SSS group, with 47.9% fewer participants in the ACE
group using any aids throughout the study. In the NHS
arm, 71 participants self-reported use of nicotine patches
(25 quits), 23 used varenicline (four quits), 35 used
nicotine gum (11 quits), 51 used e-cigarettes (15 quits)
and 73 other forms of pharmacotherapy (22 quits). In
the ACE arm, 4 participants self-reported use of nicotine
patches (one successful quit), 4 used varenicline (one quit),
5 used nicotine gum (one quit), 19 used e-cigarettes
(three quits) and 10 used other forms (three quits). At
26 weeks 83.3% of ACE participants were not using
pharmacotherapy in comparison to 40.1% of SSS partici-
pants [risk difference = 43.1% (29.4, 54.5%)].
Although non-inferiority testing was not planned,
exploration via post-hoc analyses using a 5% non-inferiority
limit for the risk difference (see Siemer et al. [13] for a de-
tailed rationale of a 5% limit in this context) suggest that
the ACEmethodwas at least as effective as the SSS interven-
tion [the absolute risk difference for the primary outcome
was 4.5 (95% CI = –1.4 to 10.4);1.4 is within the margin
of 5]. This suggests that among smokers wanting to quit,
the ACE method is neither superior nor inferior to the SSS
for achieving cessation at 26 weeks.
DISCUSSION
The SSS and Allen Carr’s Easyway (ACE) method to quit
smoking both achieved good outcomes on an intention-
Table 2 Participant ﬂow and data summary.
ACE SSS
Randomized 310 310
Eligible for inclusion in outcome analysis 310 310
Attended allocated treatment 255 213
RS smoking
Self-report of smoking at 26 weeks (> 5 cigarettes) 24 31
Self-report of smoking at 12 weeks and debriefed (> 5 cigarettes) 58 29
Self-report of abstinence throughout FU, attended and failed at least one biochemical validation session 5 0
Self-report of abstinence throughout FU, did not attend for a biochemical validation session at ﬁnal FU 0 0
No contact at ﬁnal FU 220 221
RS abstinent
Self-report of abstinence (< 5 cigarettes) throughout FU, passed biochemical validation session at ﬁnal FU 60 46
RS abstinence rate 60 of 310 46 of 310
RS = Russell Standard; FU = follow-up.
Table 3 Efﬁcacy of treatment, pharmacotherapy usage and treatment completion.
n ACE SSS χ2 P-value Odds ratio (95% CI) Risk difference (95% CI)
Treatment acceptability
Attended treatment 310/310 255 (82.3%) 213 (68.7%) < 0.001 2.11 (1.45, 3.08) 13.6% (6.6%%, 20.4%)
Veriﬁed abstinence: (ITT) analyses
4 weeks 310/310 86 (27·7%) 104 (33·5%) 0·139 0·76 (0·54, 1·07) -5·8% (13·0%, 1·5%)
12 weeks 310/310 67 (21·6%) 68 (21·9%) 1·0 0·98 (0·67, 1·44) -0·3% (6·8%, 6·2%)
26 weeks (PO) 310/310 60 (19·4%) 46 (14·8%) 0·165 1·38 (0·90, 2·10) 4·5% (1·4%, 10·4%)
Veriﬁed abstinence: participants who attended treatment analyses*
4 weeks 255/213 86 (33.7%) 104 (48·8%) 0·001 0·54, (0·37, 0·79) 15.1% (24.1%, 5.9%)
12 weeks 255/213 67 (26·3%) 68 (31·9%) 0·185 0·75 (0·50, 1·13) 5·7% (14·9%, 2·9%)
26 weeks 255/213 60 (23·5%) 44 (20·7%) 0·503 1·18 (0·75, 1·85) 2.9% (5.1%, 10·6%)
Pharmacotherapy usage
Completed study 134/161 64 (47·8%) 154 (95·7%) < 0·001 0·01 (0·00, 0·07) 47·9% (56·5%,38·4%)
Completed study and treatment 131/144 62 (47.3%) 141 (97·9%) < 0·001 0·01 (0·00, 0·05) 50·6% (59·4%,40·7%)
Pharmacotherapy-free at 26 weeks 91/89 76 (83·5%) 36 (40·4%) < 0·001 7·59 (3·71, 15·52) 43·1% (29·4%,54·5%)
ITT = intention-to-treat; PO = primary outcome; CI = conﬁdence interval; ACE = Allen Carr’s Easyway; SSS = stop smoking services. *Non-attenders are
treated as non-abstainers
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to-treat basis at 26 weeks, comparable with other trials of
stop smoking methods (including NRT and behavioural
interventions with combined pharmacotherapy) [9,14].
The pattern of ﬁndings was consistent when considering
covariates such as age, gender, nicotine dependence,
previous quit attempts and across a range of analyses
(comparing participants who attended the treatment
versus ITT and participants who re-set their quit date)
and when a complete case analysis was undertaken. As
such, these ﬁndings support and broaden the evidence
base in support of the use of such interventions in public
health settings.
Treatment initiation was signiﬁcantly higher in the
ACE arm (83%) relative to the SSS arm (69%). Without
qualitative data it is difﬁcult to conclusively interpret this
ﬁnding. However, candidate factors could include partici-
pants preferring a single, longer session, preferring a
nicotine-free approach and/or perceived novelty or per-
ceived efﬁcacy of the ACE arm. These could be explored in
future research. In relation to this, it should be noted that
participants in the ACE treatment arm were offered treat-
ment at two sites (in contrast to the SSS condition, where
only one was offered) to avoid a signiﬁcant imbalance in
days/times available (ACE sessions were only available on
Wednesdays and Thursdays at LSBU, in contrast to a.m.
or p.m. 5 days per week in the SSS). This may have inﬂu-
enced treatment uptake. A key and noteworthy difference
between treatment arms is their focus on the use of stop
smoking aids (pharmacotherapy). The SSS approach has
a strong focus on the selection and usage of NRT, Champix
and other medicinal supports. E-cigarettes are also increas-
ingly being promoted as a stop smoking aid (although not
explicitly in the current study). In contrast, the ACE
method emphasizes a nicotine-free approach to cessation
and cessation maintenance. These differences were
reﬂected in our results; among our sample, 91.3% of SSS
participants who successfully quit used NRT, Champix or
an e-cigarette. In contrast, in the ACE condition, signiﬁ-
cantly fewer people (13.3%) who successfully quit used
these forms of support.
The strengths of our study include the measurement of
smoking cessation using a continuous abstinence criterion.
Results from a recent study comparing the ACE method to
Ireland’s Quit.ie service found demonstrably superior quit
rates for the ACE method; however, they adopted a point
prevalencemethod [7].We also compared the ACEmethod
against a single intervention with high recorded efﬁcacy, in
contrast to the Quit.ie. service which features interventions
of varying intensity and efﬁcacy.
Our study had several limitations. In line with the Rus-
sell Standard, we veriﬁed successful quits using exhaled
breath carbon monoxide measurement. Although this is
considered a superior measure to self-report, other forms
of chemical veriﬁcation of being nicotine-free (i.e. cotinine
testing) are able to detect levels of nicotine consumed
further in the past. Such methods were precluded in the
current study as participants in the SSS condition were
provided with the option of using funded NRT, and both
treatment arms were free to purchase these independently
alongwith other quit aids such as e-cigarettes. As such, the
limitations surrounding carbon monoxide testing (i.e. the
duration for which one needs to be nicotine-free, sensitivity
to detect very low levels of smoking versus passive smoking
versus environmental effects and measurement error
associated with the devices themselves) limit our ﬁndings.
One way in which future research could disambiguate
tobacco-based nicotine levels from others (such as from
NRT and e-cigarettes) would be through the use of tests
of anabasine or antabine [15].
Our study excluded vulnerable patients (e.g. pregnancy,
mental illness and respiratory illness), meaning that results
are generalizable to a relatively healthy population and
may not be a true reﬂection of each service’s everyday
operation or treatment priorities.
Attrition between contacting the study and consent
was high. This may have been due to the nature of incen-
tives offered (i.e. a chance to win a holiday). It could also
reﬂect that most participants had engaged in quit attempts
before, with prior experience with one or both treatment
arms which they perceived as being unsuccessful. On a
similar note, 48.70% of participants randomized were
accounted for at the 6-month point, leaving 51.30% as lost
to follow-up. This presents a caveat in the conﬁdent
assessments of equivalence between arms, although the
potential impact of this is mitigated slightly by equal
attrition between arms.
Finally, signiﬁcantly more participants completed
treatment when randomized to the ACE intervention.
This could reﬂect a preference for the mode of delivery
offered by ACE, but could also reﬂect prior experience with
SSS which did not result in success, or were perceived as
less novel.
Our study provides evidence that the ACE method for
stopping smoking was neither superior or inferior to
leading stop smoking interventions [6,9]. Given the signif-
icantly lower usage of stop smoking aids in participants
undergoing the ACE intervention, higher treatment
completion rates, and possible cost-savings resulting from
group-based delivery, the ﬁndings support the use of this
intervention in a public health setting.
Clinical trial registration
This trial was registered with ClinicalTrials.gov
(ClinicalTrials.gov (NCT02855255), the ISRCTN
(ISRCTN23584477) and the Open Science Framework
(OSF: t6vgs).
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